Summary:
A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment with Tigulixostat in Gout Patients with Hyperuricemia
Qualified Participants Must:
18-85 years old
Have a diagnosis of gout
Qualified Participants May Receive: